• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

A.D.A.M. Medical Encyclopedia [Internet]. Atlanta (GA): A.D.A.M.; 2013.

A.D.A.M. Medical Encyclopedia.

Rubella

Three day measles; German measles

Last reviewed: February 21, 2013.

Rubella, also known as the German measles, is an infection in which there is a rash on the skin.

Congenital rubella is when a pregnant woman with rubella passes it to the baby that is still in her womb.

Causes, incidence, and risk factors

Rubella is caused by a virus that is spread through the air or by close contact.

A person with rubella may spread the disease to others from 1 week before the rash begins, until 1 - 2 weeks after the rash disappears.

Because the measles-mumps-rubella (MMR) vaccine is given to most children, rubella is much less common now. Almost everyone who receives the vaccine has immunity to rubella. Immunity means that your body has built a defense to the rubella virus.

In some adults, the vaccine may wear off and not fully protect them. Women who may become pregnant and other adults may receive a booster shot.

Children and adults who were never vaccinated against rubella may still get this infection.

Symptoms

Children generally have few symptoms. Adults may experience a fever, headache, general discomfort (malaise), and a runny nose before the rash appears. They may not notice the symptoms.

Other symptoms may include:

  • Bruising (rare)
  • Inflammation of the eyes (bloodshot eyes)
  • Muscle or joint pain

Signs and tests

A nasal or throat swab may be sent for culture.

A blood test can be done to see if a person is protected against rubella. All women who may become pregnant should have this test. If the test is negative, they will receive the vaccine.

Treatment

There is no treatment for this disease.

Patients can take acetaminophen to reduce fever.

Defects that occur with congenital rubella syndrome can be treated.

Expectations (prognosis)

Rubella is usually a mild infection.

After an infection, people have immunity to the disease for the rest of their lives.

Complications

Complications can occur in the unborn baby if the mother becomes infected during pregnancy. A miscarriage or stillbirth may occur. The child may be born with birth defects.

Calling your health care provider

Call for an appointment with your health care provider if:

  • You are a woman of childbearing age and are unsure of whether you have been vaccinated against rubella
  • You or your child develop a severe headache, stiff neck, earache, or vision problems during or after a case of rubella
  • You or your child need to receive MMR immunization (vaccine)

Prevention

There is a safe and effective vaccine to prevent rubella. The rubella vaccine is recommended for all children. It is routinely given when children are 12 - 15 months old, but is sometimes given earlier during epidemics. A second vaccination (booster) is routinely given to children ages 4 - 6. MMR is a combination vaccine that protects against measles, mumps, and rubella.

Women of childbearing age usually have a blood test to see if they have immunity to rubella. If they are not immune, women should avoid getting pregnant for 28 days after receiving the vaccine.

Those who should not get vaccinated include:

  • Women who are pregnant
  • Anyone whose immune system is affected by cancer, corticosteroid medications, or radiation treatment.

Great care is taken not to give the vaccine to a woman who is already pregnant. However, in the rare instances when pregnant women have been vaccinated, no problems have been detected in the infants.

References

  1. Weisberg SS. Vaccine preventable diseases: current perspectives in historical context. Dis Mon. 2007;53:467-528. [PubMed: 18005790]
  2. Coonrod DV, Jack BW, Boggess KA. The clinical content of preconception care: immunizations as part of preconception care. Am J Obstet Gynecol. 2008;199(6 Suppl 2):S290-S295. [PubMed: 19081423]
  3. Centers for Disease Control and Prevention. Committee on Immunization Practices (ACIP) Recommended Immunization Schedules for Persons Aged 0 Through 18 years and Adults Aged 19 Years and Older — United States, 2013. MMWR 2013; Vol. 62; p 1. [PubMed: 23364301]
  4. Centers for Disease Control and Prevention. Recommended Immunization Schedules for Persons Aged 0 Through 18 Years -- United States, 2013, MMWR 2013; Vol. 62: pp 2-8. [PubMed: 23364302]

Review Date: 2/21/2013.

Reviewed by: Neil K. Kaneshiro, MD, MHA, Clinical Assistant Professor of Pediatrics, University of Washington School of Medicine. Also reviewed by A.D.A.M. Health Solutions, Ebix, Inc., Editorial Team: David Zieve, MD, MHA, Bethanne Black, Stephanie Slon, and Nissi Wang.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only — they do not constitute endorsementscof those other sites. © 1997–2011 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

Copyright © 2013, A.D.A.M., Inc.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only — they do not constitute endorsementscof those other sites. © 1997–2011 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

Copyright © 2013, A.D.A.M., Inc.

What works?

  • Varicella and influenza vaccines may reduce morbidity in patients with blood cancers
    Viral infections cause significant disease and even death in patients with blood cancers. In the current systematic review of randomized controlled trials (RCTs) we aimed to evaluate the efficacy and safety of viral vaccines in these patients. The pre‐defined primary outcome was incidence of the infection concerned. Secondary outcomes were mortality due to the viral infection, all‐cause mortality, incidence of complications, incidence of severe viral infection, hospitalization rate, in vitro immune response and frequency of adverse effects. Eight RCTs were included. They evaluated heat‐inactivated varicella zoster virus (VZV) vaccine (two trials), influenza vaccines (five trials) and inactivated poliovirus vaccine (one trial). There were no RCTs on other viral vaccines (hepatitis A, hepatitis B, measles, mumps, rubella). Only the two trials on VZV vaccine reported our pre‐defined primary outcome. All trials reported some of the pre‐defined secondary outcomes. We found that inactivated VZV vaccine might reduce the severity of herpes zoster when given before and after stem cell transplant in adults with lymphoma or leukemia. Inactivated influenza vaccine might reduce upper and lower respiratory infections and hospitalization in adults with multiple myeloma who are undergoing chemotherapy, or children with leukemia or lymphoma within two years post‐chemotherapy. However, the quality of evidence is not high. Local adverse effects occur frequently with the vaccines, although serious adverse effects appear uncommon. Further high‐quality RCTs are needed to clarify the benefits and optimal regimens of viral vaccines for patients with blood cancers.
See all (2) ...

Figures

  • Rubella on an infant's back.
    Rubella.
    Antibodies.

PubMed Health Blog...

read all...

MedlinePlus.gov links to free, reliable, up-to-date health information from the National Institutes of Health (NIH) and other trusted health organizations.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...